Fluoxetine treatment increases trabecular bone formation in mice.

Fluoxetine treatment increases trabecular bone formation in mice. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Fluoxetine treatment increases trabecular bone formation in mice. Abstract Text:

R Battaglino,M Vokes,U ,A Sharma,D Graves,T Kohler,R ,S Yoganathan,P Stashenko,

Mounting evidence exists for the operation of a functional serotonin (5-HT) system in osteoclasts and osteoblasts, which involves both receptor activation and 5-HT reuptake. In previous work we showed that the serotonin transporter (5-HTT) is expressed in osteoclasts and that its activity is required by for osteoclast differentiation in vitro. The purpose of the current study was to determine the effect of treatment with fluoxetine, a specific serotonin reuptake inhibitor, on bone metabolism in vivo. Systemic administration of fluoxetine to Swiss-Webster mice for 6 weeks resulted in increased trabecular BV and BV/TV in femurs and vertebrae as determined by micro-computed tomography (microCT). This correlated with an increase in trabecular number, connectivity, and decreased trabecular spacing. Fluoxetine treatment also resulted in increased volume in vertebral trabecular bone. However, fluoxetine-treated mice were not protected against bone loss after ovariectomy, suggesting that its anabolic effect requires the presence of estrogen. The effect of blocking the 5-HTT on bone loss following an LPS-mediated inflammatory challenge was also investigated. Subcutaneous injections of LPS over the calvariae of Swiss-Webster mice for 5 days resulted in increased numbers of osteoclasts and net bone loss, whereas new bone formation and a net gain in bone mass was seen when LPS was given together with fluoxetine. We conclude that fluoxetine treatment in vivo leads to increased bone mass under normal physiologic or inflammatory conditions, but does not prevent bone loss associated with estrogen deficiency. These data suggest that commonly used anti-depressive agents may affect bone mass.

Fluoxetine treatment increases trabecular bone formation in mice. Publishing Authors By Initials

R Battaglino,M Vokes,U ,A Sharma,D Graves,T Kohler,R ,S Yoganathan,P Stashenko,

For similar tomography, x-ray computed research abstracts see: tomography, x-ray computed research

PUBMED ID PMID:

MEDLINE DATE:

Fluoxetine treatment increases trabecular bone formation in mice. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of cellular biochemistry

VOLUME: 100

Page Numbers: 1387-94

Journal Abbreviation: J. Cell. Biochem.

ISSN: 0730-2312

DAY: 15

MONTH: Apr

YEAR: 2007

Fluoxetine treatment increases trabecular bone formation in mice. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8205768

Fluoxetine treatment increases trabecular bone formation in mice. Keywords Mesh Terms:

KEYWORDS: Tomography, X-Ray Computed

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Fluoxetine treatment increases trabecular bone formation in mice. Information

Substance Name: Fluoxetine

Registry Number: 54910-89-3

Grant and Affiliation Information for Fluoxetine treatment increases trabecular bone formation in mice.

AFFILIATION: Department of Cytokine Biology, Forsyth Institute, Boston, Massachusetts 02115, USA. rbattaglino@Forsyth.org

Country: United States

AGENCY: United States NIDCR

GRANT: DE007378-18

ACRONYM: DE

MEDLINETA: J Cell Biochem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Fluoxetine treatment increases trabecular bone formation in mice Related Publications

• Brn3 transcription factors control terminal osteoclastogenesis.
• Fluoxetine treatment increases trabecular bone formation in mice.
• Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force.
• NHA-oc/NHA2: A mitochondrial cation-proton antiporter selectively expressed in osteoclasts.
• T Cell Response Mediated by Myeloid Cell-Derived IL-12 Is Responsible for Porphyromonas gingivalis-Induced Periodontitis in IL-10-Deficient Mice.